
    
      Participants were

        -  administered study medication approximately 28 days after initial surgery for ovarian
           cancer

        -  received the study treatment regimen of up to one year unless there was disease
           progression, unacceptable toxicity, death, participant refusal, or treatment delay
           beyond the time frame permitted for each treatment

      Participants were followed for survival for a minimum 3 years from the date of enrollment
    
  